ERBB2 and breast neoplasm: For clinical HER2 status, most basal-like breast tumors were HER2-normal, most HER2-enriched subtype cases were with HER2 over-expression, and the luminal-B tended to report a higher propensity of HER2 over-expression than the luminal-A subtype, regardless of predictive methods (PLS-regression or PAM50 SSP).